HRP20211443T1 - Izbor neoepitopa kao ciljeva specifičnih za bolest za trerapiju sa povećanom efikasnošću - Google Patents
Izbor neoepitopa kao ciljeva specifičnih za bolest za trerapiju sa povećanom efikasnošću Download PDFInfo
- Publication number
- HRP20211443T1 HRP20211443T1 HRP20211443TT HRP20211443T HRP20211443T1 HR P20211443 T1 HRP20211443 T1 HR P20211443T1 HR P20211443T T HRP20211443T T HR P20211443TT HR P20211443 T HRP20211443 T HR P20211443T HR P20211443 T1 HRP20211443 T1 HR P20211443T1
- Authority
- HR
- Croatia
- Prior art keywords
- disease
- neoepitope
- gene
- copies
- mutated allele
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 9
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims 13
- 108700028369 Alleles Proteins 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 108700039887 Essential Genes Proteins 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
Claims (11)
1. Postupak za određivanje podobnosti neoepitopa koji je rezultat mutacije specifične za bolest na alelu u genu (mutirani alel) kao cilja specifičnog za bolest, naznačen time, što uključuje određivanje, u oboljeloj stanici ili populaciji oboljelih stanica, broja kopija mutiranog alela koji kodira neoepitop, pri čemu broj kopija mutiranog alela koji je veći od 2 ukazuje na podobnost neoepitopa kao cilja specifičnog za bolest, pri čemu je bolest rak i pri čemu što je viši broj kopija mutiranog alela, viša je podobnost neoepitopa kao cilja specifičnog za bolest.
2. Postupak prema patentnom zahtjevu 1, naznačen time, što broj kopija mutiranog alela koji je veći od 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, ili veći od 100 ukazuje na podobnost neoepitopa kao cilja specifičnog za bolest.
3. Postupak prema patentnim zahtjevima 1 ili 2, naznačen time, što je odnos broja kopija mutiranog alela prema ukupnom broju kopija nukleotidnog mjesta na kojem se mutacija mapira veći od 0.5, pri čemu, poželjno, odnos iznosi 1.
4. Postupak prema patentnom zahtjevu 3, naznačen time, da što je viši odnos broja kopija mutiranog alela prema ukupnom broju kopija nukleotidnog mjesta na kojem se mutacija mapira, viša je podobnost neoepitopa kao cilja specifičnog za bolest.
5. Postupak prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, što je gen vodeći gen čija ekspresija rezultira transformacijom stanice u kancerogeni fenotip ili čiji izostanak ekspresije rezultira time da kancerogena stanica izgubi svoj kancerogeni fenotip.
6. Postupak prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, što je gen esencijalni gen, pri čemu, poželjno,
esencijalni gen je gen koji, kada je utišan ili je njegova ekspresija smanjena, rezultira bar ometenim rastom ili smanjenim fitnesom stanice u kojoj se esencijalni gen eksprimira, poželjno oboljeloj stanici; ili
se esencijalni gen eksprimira u velikom broju različitih tkiva i eksprimira se sa minimalnim RPKM pragom većim od 0.
7. Postupak prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, što je mutacija specifična za bolest varijacija pojedinačnog nukleotida.
8. Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, što je neoepitop identificiran postupkom koji uključuje sekvenciranje genoma oboljele stanice ili njegovog dijela.
9. Postupak za davanje cjepiva, naznačen time, što uključuje identificiranje podobnog neoepitopa ili kombinacije podobnih neoepitopa prema postupku iz bilo kojeg od patentnih zahtjeva 1 do 8.
10. Postupak prema patentnom zahtjevu 9, naznačen time, što cjepivo uključuje peptid ili polipeptid koji sadrže jedan ili više podobnih neoepitopa ili kombinaciju podobnih neoepitopa, ili nukleinsku kiselinu koja kodira navedeni peptid ili polipeptid.
11. Postupak prema patentnom zahtjevu 10, naznačen time, što je nukleinska kiselina RNK.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2016067348 | 2016-07-20 | ||
| PCT/EP2017/068226 WO2018015433A2 (en) | 2016-07-20 | 2017-07-19 | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy |
| EP17743311.7A EP3488443B8 (en) | 2016-07-20 | 2017-07-19 | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211443T1 true HRP20211443T1 (hr) | 2021-12-24 |
Family
ID=59399416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211443TT HRP20211443T1 (hr) | 2016-07-20 | 2017-07-19 | Izbor neoepitopa kao ciljeva specifičnih za bolest za trerapiju sa povećanom efikasnošću |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20190189241A1 (hr) |
| EP (2) | EP3967324A1 (hr) |
| JP (2) | JP7171543B2 (hr) |
| KR (2) | KR20230019223A (hr) |
| CN (2) | CN109477149A (hr) |
| BR (1) | BR112018077122A8 (hr) |
| CA (1) | CA3031003A1 (hr) |
| CY (1) | CY1124551T1 (hr) |
| DK (1) | DK3488443T3 (hr) |
| ES (1) | ES2890424T3 (hr) |
| HR (1) | HRP20211443T1 (hr) |
| HU (1) | HUE056660T2 (hr) |
| IL (2) | IL311369A (hr) |
| LT (1) | LT3488443T (hr) |
| MX (4) | MX2019000733A (hr) |
| PL (1) | PL3488443T3 (hr) |
| PT (1) | PT3488443T (hr) |
| RS (1) | RS62390B1 (hr) |
| SG (2) | SG10201912678QA (hr) |
| SI (1) | SI3488443T1 (hr) |
| WO (1) | WO2018015433A2 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019505512A (ja) | 2016-01-08 | 2019-02-28 | バッシボディ アクスイェ セルスカプ | 治療用抗癌ネオエピトープワクチン |
| AU2018214556A1 (en) | 2017-02-01 | 2019-08-15 | Modernatx, Inc. | Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides |
| US11969463B2 (en) * | 2017-08-10 | 2024-04-30 | Good T Cells, Inc. | Method for activating T cells for cancer treatment |
| CA3077221A1 (en) * | 2017-10-12 | 2019-04-18 | Nantomics, Llc | Cancer score for assessment and response prediction from biological fluids |
| CN109294983A (zh) * | 2018-09-30 | 2019-02-01 | 北京鼎成肽源生物技术有限公司 | 一种lff2细胞 |
| CN111402954B (zh) * | 2019-01-02 | 2023-07-21 | 中国人民解放军军事科学院军事医学研究院 | 一种辨识与预测空间辐射损伤防护药靶相关人类基因的方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| EP0871747A1 (en) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunostimulation mediated by gene-modified dendritic cells |
| US20090191556A1 (en) | 2006-04-12 | 2009-07-30 | Medical Research Council | Method |
| JP2010537200A (ja) | 2007-08-21 | 2010-12-02 | ワシントン ユニバーシティー | 改善されたアルツハイマー診断法 |
| BRPI0816393A2 (pt) | 2007-09-07 | 2015-03-03 | Fluidigm Corp | Método para determinar o número de cópias relativo de uma sequência de polinucleotídeo alvo em um genoma de um indivíduo |
| BR112012029066A2 (pt) * | 2010-05-14 | 2020-09-01 | The General Hospital Corporation | composições e processos de identificação de neoantígenos específicos de tumor. |
| HUE062102T2 (hu) * | 2011-05-24 | 2023-09-28 | BioNTech SE | Individualizált vakcinák a rák ellen |
| CN104080797A (zh) * | 2011-11-11 | 2014-10-01 | 弗雷德哈钦森癌症研究中心 | 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法 |
| US9569586B2 (en) * | 2012-02-13 | 2017-02-14 | Albert Rubben | Algorithm for modification of somatic cancer evolution |
| JP5972448B2 (ja) | 2012-04-05 | 2016-08-17 | ビージーアイ ダイアグノーシス カンパニー リミテッドＢｇｉ Ｄｉａｇｎｏｓｉｓ Ｃｏ．， Ｌｔｄ． | コピー数変異を検出する方法及びシステム |
| EP3511425A1 (en) * | 2012-07-12 | 2019-07-17 | Persimmune, Inc. | Personalized cancer vaccines and adoptive immune cell therapies |
| WO2014014497A1 (en) | 2012-07-20 | 2014-01-23 | Verinata Health, Inc. | Detecting and classifying copy number variation in a cancer genome |
| US20140256571A1 (en) | 2013-03-06 | 2014-09-11 | Life Technologies Corporation | Systems and Methods for Determining Copy Number Variation |
| KR102341899B1 (ko) * | 2013-04-07 | 2021-12-21 | 더 브로드 인스티튜트, 인코퍼레이티드 | 개인맞춤화 신생물 백신을 위한 조성물 및 방법 |
| US20150331992A1 (en) * | 2014-05-15 | 2015-11-19 | Ramot At Tel-Aviv University Ltd. | Cancer prognosis and therapy based on syntheic lethality |
| KR20240010089A (ko) * | 2015-10-12 | 2024-01-23 | 난토믹스, 엘엘씨 | 네오에피토프의 반복적 발견 및 이에 대한 적응성 면역치료 및 방법 |
| RU2729116C2 (ru) * | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
| WO2018005276A1 (en) * | 2016-06-29 | 2018-01-04 | The Johns Hopkins University | Neoantigens as targets for immunotherapy |
-
2017
- 2017-07-19 EP EP21178672.8A patent/EP3967324A1/en active Pending
- 2017-07-19 HU HUE17743311A patent/HUE056660T2/hu unknown
- 2017-07-19 KR KR1020237002958A patent/KR20230019223A/ko not_active Application Discontinuation
- 2017-07-19 PL PL17743311T patent/PL3488443T3/pl unknown
- 2017-07-19 IL IL311369A patent/IL311369A/en unknown
- 2017-07-19 SG SG10201912678QA patent/SG10201912678QA/en unknown
- 2017-07-19 HR HRP20211443TT patent/HRP20211443T1/hr unknown
- 2017-07-19 EP EP17743311.7A patent/EP3488443B8/en active Active
- 2017-07-19 JP JP2019502699A patent/JP7171543B2/ja active Active
- 2017-07-19 SG SG11201900132QA patent/SG11201900132QA/en unknown
- 2017-07-19 SI SI201730919T patent/SI3488443T1/sl unknown
- 2017-07-19 WO PCT/EP2017/068226 patent/WO2018015433A2/en unknown
- 2017-07-19 CN CN201780044824.0A patent/CN109477149A/zh active Pending
- 2017-07-19 CA CA3031003A patent/CA3031003A1/en active Pending
- 2017-07-19 LT LTEPPCT/EP2017/068226T patent/LT3488443T/lt unknown
- 2017-07-19 MX MX2019000733A patent/MX2019000733A/es unknown
- 2017-07-19 CN CN202311634920.4A patent/CN117757931A/zh active Pending
- 2017-07-19 KR KR1020197002010A patent/KR102516166B1/ko active IP Right Grant
- 2017-07-19 RS RS20211138A patent/RS62390B1/sr unknown
- 2017-07-19 PT PT177433117T patent/PT3488443T/pt unknown
- 2017-07-19 US US16/318,895 patent/US20190189241A1/en active Pending
- 2017-07-19 BR BR112018077122A patent/BR112018077122A8/pt unknown
- 2017-07-19 ES ES17743311T patent/ES2890424T3/es active Active
- 2017-07-19 IL IL264203A patent/IL264203B2/en unknown
- 2017-07-19 DK DK17743311.7T patent/DK3488443T3/da active
-
2019
- 2019-01-17 MX MX2023009369A patent/MX2023009369A/es unknown
- 2019-01-17 MX MX2023009370A patent/MX2023009370A/es unknown
- 2019-01-17 MX MX2023009371A patent/MX2023009371A/es unknown
-
2021
- 2021-09-14 CY CY20211100808T patent/CY1124551T1/el unknown
-
2022
- 2022-11-02 JP JP2022176504A patent/JP2023009120A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211443T1 (hr) | Izbor neoepitopa kao ciljeva specifičnih za bolest za trerapiju sa povećanom efikasnošću | |
| JP6929791B2 (ja) | エピゲノム編集のための組成物および方法 | |
| EP3382018B1 (en) | Dna methylation editing kit and dna methylation editing method | |
| ES2670531T3 (es) | Un método para producir una escisión de ADN precisa utilizando la actividad nickasa de Cas9 | |
| Yang et al. | Suppression of methylation-mediated transcriptional gene silencing by βC1-SAHH protein interaction during geminivirus-betasatellite infection | |
| WO2017024602A1 (zh) | 一种测定非同源末端连接修复活性的方法 | |
| Conradie et al. | Distinct polymorphisms in a single herpesvirus gene are capable of enhancing virulence and mediating vaccinal resistance | |
| US20240076678A1 (en) | Compositions and methods for epigenetic editing | |
| Yu et al. | Virus-encoded miR-155 ortholog is an important potential regulator but not essential for the development of lymphomas induced by very virulent Marek's disease virus | |
| CA3134400A1 (en) | Method for identifying functional elements | |
| Patrushev et al. | Mutations in mitochondrial DNA and approaches for their correction | |
| JP6452266B2 (ja) | ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子 | |
| Huang et al. | Synergistic effects of arsenic trioxide combined with ascorbic acid in human osteosarcoma MG-63 cells: a systems biology analysis. | |
| Shen et al. | Osteoponin promoter controlled by DNA methylation: aberrant methylation in cloned porcine genome | |
| Hudson et al. | Changes in global gene expression in response to chemical and genetic perturbation of chromatin structure | |
| Doerfler | Epigenetic mechanisms in human adenovirus type 12 oncogenesis | |
| Therizols et al. | Ribosomal RNA methylation and cancer | |
| Li et al. | Gga-miR-181a modulates ANP32A expression and inhibits MDCC-MSB-1 cell | |
| Chatterjee et al. | Pontin/Reptin-associated complexes differentially impact plant development and viral pathology | |
| zouabi et al. | Molecular underpinnings and environmental drivers of spontaneous loss of heterozygosity in Drosophila intestinal stem cells | |
| Wickramasinghe et al. | Footprints of past pandemics in the human genome | |
| Cho et al. | The evolutionary and genetic patterns of African swine fever virus | |
| Yasuhiko et al. | LTRs of Endogenous Retroviruses as a Source of Tbx6 Binding Sites | |
| Van et al. | Genomics and big data: research, development and applications | |
| Dennin | Fundamentals of extrachromosomal circular DNA in human cells-Genetic activities as regards cancer promotion alongside chromosomal DNA |